Clinical review on triglycerides

Abstract Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies have established that triglyceride-rich lipoproteins (TRL) and their remnants as important contributors to ASCVD while severe hypertriglyceridaemia raises risk of pancreatitis. While low-density lipoprotei...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 2020-01, Vol.41 (1), p.99-109c
Main Authors: Laufs, Ulrich, Parhofer, Klaus G, Ginsberg, Henry N, Hegele, Robert A
Format: Article
Language:English
Subjects:
Clinical Review
Humans
Hypertriglyceridemia - therapy
Life Style
Triglycerides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Hypertriglyceridaemia is a common clinical problem. Epidemiologic and genetic studies have established that triglyceride-rich lipoproteins (TRL) and their remnants as important contributors to ASCVD while severe hypertriglyceridaemia raises risk of pancreatitis. While low-density lipoprotein is the primary treatment target for lipid lowering therapy, secondary targets that reflect the contribution of TRL such as apoB and non-HDL-C are recommended in the current guidelines. Reduction of severely elevated triglycerides is important to avert or reduce the risk of pancreatitis. Here we discuss interventions for hypertriglyceridaemia, including diet and lifestyle, established treatments such as fibrates and omega-3 fatty acid preparations and emerging therapies, including various biological agents.
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehz785